Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 29th Preview)
-
DMD cell therapy: HOPE-3 phase 3 signals on function and cardiac preservation
Capricor Therapeutics’ donor-cell bloodstream therapy deramiocel produced statistically significant slowing of upper-limb functional decline in boys and young men with advanced Duchenne muscular dystrophy in the HOPE-3 phase 3 trial, published in The Lancet. The randomized study enrolled 106 patients ages 10 to 22 across 20 U.S. sites and delivered deramiocel via IV drip every three months for one year versus placebo. After 12 months, deramiocel-treated participants declined more slowly in arm movement: overall arm function declined about 54% more slowly than placebo, with elbow movement about 65% more slowly. A clearer differentiation of cardiac outcomes emerged in subgroups with baseline heart disease and analyzable cardiac scans, where heart function was better preserved versus placebo. The therapy also appeared to reduce markers consistent with heart scarring expansion in a smaller set of patients with before-and-after scans. Across the trial, no deaths were reported and safety was generally favorable, though allergic-type reactions were more common in the deramiocel arm (42% vs 15%), with most events mild or moderate. Regulatory review pressure remains, as the FDA has already posted a critical analysis challenging how effectively deramiocel separated from placebo on key endpoints, according to public review materials discussed in parallel coverage ahead of an FDA advisory committee.
-
Autoimmune T-cell engagers: Vertex doubles down on AbCellera’s TCE platform
AbCellera and Vertex Pharmaceuticals expanded their T-cell engager strategy with a new collaboration to discover, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will lead discovery and early development, while Vertex funds all R&D costs and gains rights to advance and commercialize resulting candidates. The agreement includes $28 million in total upfront payments to AbCellera plus potential preclinical, development, regulatory, and commercial milestones and tiered royalties on net sales. Vertex’s inclusion of cell line and early manufacturing through Phase 1 is also part of the deal scope. The collaboration adds to a broader industry shift toward platform partnerships for next-generation TCE modalities, with Vertex seeking to build out beyond its current concentration in cystic fibrosis and other legacy franchises.
-
Regulatory scrutiny in melanoma gene therapy: Replimune faces continued FDA skepticism
Regulatory and investor attention stayed focused on Replimune’s RP-1 as FDA reviewers reiterated concerns about the company’s statistical approach and the adequacy of evidence in a single-arm melanoma trial ahead of a Cellular, Tissue, and Gene Therapies advisory committee meeting. Briefing materials characterized the company’s analysis as failing to prove that RP-1 works as intended in its intended population. In separate coverage, FDA staff issues described rejection-risk dynamics repeatedly for RP-1, tied to how objective response rate and duration of response were derived compared with FDA analyses. Replimune has reportedly already received multiple complete response letters from the FDA. The episode highlights how regulators are treating design-for-approval claims in complex, locally administered cell-gene therapy settings where robust control groups and endpoint validation can be central to potential clearance.
-
Precision microbiology and diagnostics: 10x Genomics and Lausanne Hospital target tumor biomarkers
10x Genomics announced a multi-year collaboration with Lausanne University Hospital to use single-cell and spatial technologies to discover tumor biomarkers tied to treatment response and resistance across advanced solid cancers. The work will use 10x’s Flex APEX and Xenium platforms, with an expansion plan toward the company’s Atera platform. The collaboration will analyze tumor samples from patients evaluated by clinical molecular tumor boards, integrating multimodal data with clinical outcome records. Target solid cancer types include non-small cell lung cancer, breast cancer, bladder cancer, and melanoma. The stated goal is to identify clinically actionable biomarkers that improve patient selection and support future diagnostic integration into routine tumor board decision-making.
-
Biotech takeout: Argenx agrees $2.2B acquisition of Forte for FB102 autoimmunity expansion
Argenx agreed to acquire Forte Biosciences for about $2.2 billion, adding FB102, an anti-CD122 monoclonal antibody, as a potential pipeline-in-a-product. The proposed deal follows Forte’s reported Phase Ib signal in vitiligo, where FB102 achieved a 29.6% mean Facial Vitiligo Area Scoring Index improvement at week 24 versus baseline, with statistically significant improvements reported as early as day 64. Coverage also pointed to FB102 data in celiac disease and planned Phase II readouts, with additional autoimmune indications such as alopecia areata discussed as potential expansion areas. Argenx positioned FB102 as expanding its immunology platform beyond its blockbuster Vyvgart mechanism. The transaction is subject to tender and Hart-Scott-Rodino review, and is planned to be funded from cash on hand, underscoring continued appetite for clinical-stage immunology assets that can pair with platform development and commercial reach.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.